retatrutide phase 2 nejm 2023 obesity trial jastreboff 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide for Obesity: Phase 2
Description
active component military members ranged from 15.0% in August 2020 to 19.3% in April 2021, confirming a further growth trend
Step 1 - Pre-book a consultation Our expert pharmacists will ask you about your weight loss goals, lifestyle, nutrition, and weight management challenges
A moderate dosage titration method is advised to mitigate adverse effects when commencing medication (Bettge et al
Evidence from trials describes groups, not personal outcomes
10.1001/jamaophthalmol.2024.2296 [DOI] [PMC free article] [PubMed] [Google Scholar] He W., Wang H., Zhao C., Tian X., Li L., Wang H
